Skip to search formSkip to main contentSkip to account menu

Overall Survival

A measure of the time until death from any cause.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
BACKGROUND An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression‐free survival, as… 
Highly Cited
2017
Highly Cited
2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
BACKGROUND Nivolumab combined with ipilimumab resulted in longer progression‐free survival and a higher objective response rate… 
Highly Cited
2016
Highly Cited
2016
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Highly Cited
2015
Highly Cited
2015
Improved overall survival in melanoma with combined dabrafenib and trametinib.
BACKGROUND The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously… 
Review
2011
Review
2011
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
BACKGROUND Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more… 
Highly Cited
2010
Highly Cited
2010
Improved survival with ipilimumab in patients with metastatic melanoma.
BACKGROUND An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3… 
Highly Cited
2010
Highly Cited
2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised…
Highly Cited
2009
Highly Cited
2009
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
PURPOSE A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free… 
Highly Cited
2009
Highly Cited
2009
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Highly Cited
2008
Highly Cited
2008
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
PURPOSE As treatment options expand for metastatic colorectal cancer (mCRC), a blood marker with a prognostic and predictive role… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)